Israel’s Syremis Therapeutics develops treatments for severe mental illness. Its ST-905 is a potent M1/M4 muscarinic agonist for schizophrenia and other serious neuropsychiatric conditions, currently in Phase 1 trials. Also ST-901 for major depressive disorder and bipolar depression.

https://www.calcalistech.com/ctechnews/article/s1wxgkrxwx

https://syremis.com/#pipe